LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease

Neurogenetics

Volumn 11, Issue 1, 2010, Pages 121-125

  Gan Or, Z ^a,b   Bar Shira, A ^a   Mirelman, A ^a   Gurevich, T ^a,b   Kedmi, M ^a   Giladi, N ^a,b   Orr Urtreger, A ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

GBA; Glucocerebrosidase; Initial symptoms; LRRK2; Parkinson's disease

Indexed keywords

GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2;

ADULT; AGED; ARTICLE; BALANCE DISORDER; BRADYKINESIA; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE STIFFNESS; PARKINSON DISEASE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES;

EID: 76549089808     PISSN: 13646745     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10048-009-0198-9     Document Type: Article

References (20)

1. DG Healy M Falchi SS O'Sullivan, et al. 2008 Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol 7 583 590 10.1016/S1474-4422(08)70117-0 10.1016/S1474-4422(08)70117-0 1:CAS:528:DC%2BD1cXptVWju7o%3D 18539534
2. E Rogaeva J Hardy 2008 Gaucher and Parkinson diseases: unexpectedly related Neurology 70 2272 2273 10.1212/01.wnl.0000314657.92762.0f 10.1212/01.wnl.0000314657.92762.0f 18541881
3. LJ Ozelius G Senthil R Saunders-Pullman, et al. 2006 LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews N Engl J Med 354 424 425 10.1056/NEJMc055509 10.1056/NEJMc055509 1:CAS:528:DC%2BD28XnslWisw%3D%3D 16436782 (Pubitemid 43145083)
4. LN Clark BM Ross Y Wang, et al. 2007 Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease Neurology 69 1270 1277 10.1212/01.wnl.0000276989.17578.02 10.1212/01.wnl.0000276989.17578.02 1:CAS:528:DC%2BD2sXhtVWqsrjE 17875915 (Pubitemid 47429028)
5. Z Gan-Or N Giladi U Rozovski, et al. 2008 Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset Neurology 70 2277 2283 10.1212/01.wnl.0000304039.11891.29 10.1212/01.wnl.0000304039.11891.29 1:CAS:528:DC%2BD1cXmsFylsrk%3D 18434642
6. A Orr-Urtreger C Shifrin U Rozovski, et al. 2007 The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 69 1595 1602 10.1212/01.wnl.0000277637.33328.d8 10.1212/01.wnl. 0000277637.33328.d8 1:CAS:528:DC%2BD2sXhtFekt7zE 17938369 (Pubitemid 350287143)
7. E Beutler T Gelbart CR Scott 2005 Hematologically important mutations: Gaucher disease Blood Cells Mol Dis 35 355 364 10.1016/j.bcmd.2005.07.005 10.1016/j.bcmd.2005.07.005 1:CAS:528:DC%2BD2MXht1aqu7rE 16185900 (Pubitemid 41627801)
8. DJ Moore 2008 The biology and pathobiology of LRRK2: implications for Parkinson's disease Parkinsonism Relat Disord 14 Suppl 2 S92 S98 10.1016/j.parkreldis.2008.04.010 10.1016/j.parkreldis.2008.04.010 18602856
9. S Lesage S Belarbi A Troiano, et al. 2008 Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? Neurology 71 1550 1552 10.1212/01.wnl.0000338460.89796.06 10.1212/01.wnl.0000338460.89796.06 1:STN:280:DC%2BD1cjhslCiuw%3D%3D 18981379
10. RJ Uitti Y Baba ZK Wszolek, et al. 2005 Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort Parkinsonism Relat Disord 11 139 145 10.1016/j.parkreldis.2004.10.007 10.1016/j.parkreldis.2004.10.007 15823477
11. RA Roos JC Jongen EA van der Velde 1996 Clinical course of patients with idiopathic Parkinson's disease Mov Disord 11 236 242 10.1002/mds.870110304 10.1002/mds.870110304 1:STN:280:DyaK28zgtVCrtQ%3D%3D 8723138 (Pubitemid 26138820)
12. R Djaldetti S Hassin-Baer MJ Farrer, et al. 2008 Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel J Neural Transm 115 1279 1284 10.1007/s00702-008-0074-z 10.1007/s00702-008-0074-z 1:STN:280:DC%2BD1crkslWgtQ%3D%3D 18665323
13. S Papapetropoulos N Adi J Ellul, et al. 2007 A prospective study of familial versus sporadic Parkinson's disease Neurodegener Dis 4 424 427 10.1159/000107702 10.1159/000107702 17934325 (Pubitemid 47557283)
14. S Papapetropoulos C Paschalis A Athanassiadou, et al. 2001 Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease J Neurol Neurosurg Psychiatry 70 662 665 10.1136/jnnp. 70.5.662 10.1136/jnnp.70.5.662 1:STN:280:DC%2BD3M3hvFehug%3D%3D 11309462
15. MJ Devine PA Lewis 2008 Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2 FEBS J 275 5748 5757 10.1111/j.1742-4658.2008. 06707.x 10.1111/j.1742-4658.2008.06707.x 1:CAS:528:DC%2BD1cXhsV2mur3O 19021752
16. CC Ho HJ Rideout E Ribe, et al. 2009 The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration J Neurosci 29 1011 1016 10.1523/JNEUROSCI.5175-08.2009 10.1523/JNEUROSCI.5175-08. 2009 1:CAS:528:DC%2BD1MXhs1KqsbY%3D 19176810
17. AK Liou RK Leak L Li, et al. 2008 Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway Neurobiol Dis 32 116 124 10.1016/j.nbd.2008.06.016 10.1016/j.nbd.2008.06.016 1:CAS:528:DC%2BD1cXhtFantbvJ 18675914
18. I Ron M Horowitz 2005 ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity Hum Mol Genet 14 2387 2398 10.1093/hmg/ddi240 10.1093/hmg/ddi240 1:CAS:528:DC%2BD2MXpsFams7w%3D 16000318 (Pubitemid 41418000)
19. AM Cuervo L Stefanis R Fredenburg, et al. 2004 Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 305 1292 1295 10.1126/science.1101738 10.1126/science.1101738 1:CAS:528:DC%2BD2cXmvFCit7w%3D 15333840 (Pubitemid 39129234)
20. J Bras A Singleton MR Cookson, et al. 2008 Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease FEBS J 275 5767 5773 10.1111/j.1742-4658.2008.06709.x 10.1111/j.1742-4658.2008. 06709.x 1:CAS:528:DC%2BD1cXhsV2mur3I 19021754